Omnipaque 300mg Injection

For each imaging procedure, specific dosage forms, concentrations, and presentations are recommended. Individualize the concentration and volume according to the specific dosing tables and accounting for factors such as age, body weight, and condition of the patient, and the equipment and imaging technique used. See full prescribing information for complete dosing and administration information.

Directions from the U.S. FDA-approved label for Iohexol — your doctor or pharmacist may advise differently.

OMNIPAQUE for hysterosalpingography is contraindicated during pregnancy or suspected pregnancy, menstruation or when menstruation is imminent, within 6 months after termination of pregnancy, within 30 days after conization or curettage, when signs of infection are present in any portion of the genital tract including the external genitalia, and when reproductive tract neoplasia is known or suspected because of the risk of peritoneal spread of neoplasm.

Excerpt from the U.S. FDA-approved label for Iohexol. Talk to a pharmacist or doctor before use.

Hypersensitivity Reactions: Life-threatening or fatal reactions can occur. Always have emergency equipment and trained personnel available. Acute Kidney Injury: Acute injury including renal failure can occur. Minimize dose and maintain adequate hydration to minimize risk. Cardiovascular Adverse Reactions: Hemodynamic disturbances including shock and cardiac arrest may occur during or after administration. Thyroid Dysfunction in Pediatric Patients 0 to 3 Years of Age: Individualize thyroid function monitoring based on risk factors such as prematurity.

Warnings and precautions excerpt from the U.S. FDA-approved label for Iohexol — not a complete list. Talk to a pharmacist or doctor before use.

The following clinically significant adverse reactions are described elsewhere in the labeling: Risks Associated with Intrathecal Administration of OMNIPAQUE Injection 140 mg Iodine/mL and 350 mg Iodine/mL Risks Associated with Parenteral Administration of OMNIPAQUE Oral Solution Hypersensitivity Reactions Acute Kidney Injury Cardiovascular Adverse Reactions Thromboembolic Events Thyroid Dysfunction in Pediatric Patients 0 to…

Excerpt from the U.S. FDA-approved label for Iohexol — not a complete list. Talk to a pharmacist or doctor about side effects.

2 brands · 1 maker in the NepalDoc catalog — see the full Iohexol guide →

OMNIPAQUE Injection: Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). May be stored in a contrast media warmer for up to one month, not to exceed 37°C (98.6°F). OMNIPAQUE Oral Solution: Store between 0°C and 30°C (32°F to 86°F). Protect from light. Do not freeze.

Storage information from the U.S. FDA-approved label for Iohexol.